 A potential breakthrough in the treatment of stomach cancer helped boost shares of Five Prime Therapeutics higher by as much as 386 to 26.00 in Tuesday pre-market trades. The small-cap biotechnology company said on Monday that its phase 2 FIGHT trial evaluating bemarituzumab in front-line advanced gastric cancer and gastroesophageal junction cancer met all 3 pre-determined efficacy endpoints. 